Testolone (RAD-140)
RAD-140 · RAD
Potent SARM; suppression and hepatotoxicity reported at higher doses.
Key takeaways
- Potent SARM with a ~45-hour half-life; once-daily dosing, levels accumulate over the first week.
- Reached a first-in-human phase 1 trial (breast cancer), but published human PK data remain limited.
- Suppression, lipid disruption, and liver enzyme elevation are common at off-label doses.
- Unapproved, WADA-prohibited, and often mislabeled or contaminated in grey-market products.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Physique (community) | 5–20 mg | Oral | Once daily | 6–8 weeks |
Pharmacokinetic summary
- Model tier
- Advanced (t½ + Cmax + Tmax + F)
- Half-life
- 44.7 hours
- Cmax
- 447 ng/mL
- Tmax
- 0.3 days
- Bioavailability
- 60%
- Typical dose
- 5–20 mg
Harm reduction
- Aromatizes
- No
- Hepatotoxicity
- mild
- Injection frequency
- Oral, daily
Frequently asked questions
Was RAD-140 ever tested in humans?
Yes: a first-in-human phase 1 trial in ER-positive, HER2-negative metastatic breast cancer, published in 2022. That's oncology dose-escalation work, not physique-use safety data; nothing published covers community doses.
How suppressive is testolone?
Reported as moderately to strongly suppressive at common off-label doses (10–20 mg), with LH, FSH, and total testosterone drops visible on bloodwork. No trial quantifies it; expect suppression and plan PCT accordingly.
Is RAD-140 liver toxic?
Case reports link SARM use, including RAD-140, to drug-induced liver injury, and liver enzyme elevations are common at off-label doses. ALT and AST belong in any bloodwork panel during a cycle.
References
- PubMed RAD-140 case
- First-in-human phase 1 study of RAD140, Clin Breast Cancer 2022 — Oncology dose-escalation trial; the only published human RAD-140 study.
Related compounds
Ostarine (MK-2866 / Enobosarm)
Non-steroidal SARM; mild, used in cutting/recomp. Simple model (estimated).
Ligandrol (LGD-4033)
Potent SARM for lean mass; suppression evident at higher doses.
Andarine (S4)
SARM with notable vision-related side effects; short half-life requiring divided dosing.
Protocols featuring Testolone (RAD-140)
Comments
Loading comments…